Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

(2016) Andras Fogarasi et al.   BMC Neurology

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

(2016) Klemens Budde et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2

(2016) John Bissler et al.   JOURNAL OF UROLOGY

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

(2016) Jacqueline A French et al.   LANCET

Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial

(2016) Nicolás Roberto Robles et al.   Orphanet Journal of Rare Diseases

Management of side effects of mTOR inhibitors in tuberous sclerosis patients

(2016) Krzysztof Sadowski et al.   Pharmacological Reports

Pubertal Development in Pediatric Kidney Transplant Patients Receiving Mammalian Target of Rapamycin Inhibitors or Conventional Immunosuppression

(2016) Julia Förster et al.   TRANSPLANTATION

Tuberous sclerosis complex

(2016) Elizabeth P. Henske et al.   Nature Reviews Disease Primers

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

(2016) David N. Franz et al.   PLoS One

Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands

(2015) Marinus J.C. Eijkemans et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis

(2015) David N. Franz et al.   ANNALS OF NEUROLOGY

Neurological and neuropsychiatric aspects of tuberous sclerosis complex

(2015) Paolo Curatolo et al.   LANCET NEUROLOGY

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial

(2015) John J. Bissler et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments

(2015) Julian Sampson et al.   SEMINARS IN NEUROLOGY

Linear growth in pediatric renal transplant recipients receiving sirolimus

(2015) Leonard C. Hymes et al.   PEDIATRIC TRANSPLANTATION

Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists

(2014) Denise A. Yardley   Clinical Breast Cancer

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

(2014) David Neal Franz et al.   LANCET ONCOLOGY

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1

(2014) J. C. Kingswood et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex

(2014) John C Kingswood et al.   Orphanet Journal of Rare Diseases

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors

(2013) Gianluigi Zaza et al.   Clinical & Developmental Immunology

Epilepsy in TSC: Certain etiology does not mean certain prognosis

(2013) Aglaia Vignoli et al.   EPILEPSIA

Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex

(2013) Karen Agricola et al.   JOURNAL OF NEUROSCIENCE NURSING

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

(2013) Darcy A. Krueger et al.   PEDIATRIC NEUROLOGY

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

(2013) Mary E. Peterson   SUPPORTIVE CARE IN CANCER

Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients

(2013) Heiko Billing et al.   TRANSPLANT INTERNATIONAL

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial

(2012) Cristina Cabrera-López et al.   Orphanet Journal of Rare Diseases

The impact of sirolimus on sex hormones in male adolescent kidney recipients

(2012) Teresa M. Cavanaugh et al.   PEDIATRIC TRANSPLANTATION

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

(2011) D. M. Davies et al.   CLINICAL CANCER RESEARCH

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

De novo Therapy with Everolimus, Low-Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation

(2010) L. Pape et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Therapeutic targeting of mTOR in tuberous sclerosis

(2009) Julian R. Sampson   BIOCHEMICAL SOCIETY TRANSACTIONS

The natural history of epilepsy in tuberous sclerosis complex

(2009) Catherine J. Chu-Shore et al.   EPILEPSIA

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

(2009) M. E. A. P. M. Adriaensen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Tuberous sclerosis

(2008) Paolo Curatolo et al.   LANCET

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE